These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

375 related items for PubMed ID: 11187869

  • 1. The maintenance of tolerance after successful immune tolerance induction in hemophilia A and B: the North American Registry. Factor VIII/IX Subcommittee of the International Society for Thrombosis and Hemostasis.
    DiMichele D, Kroner B, Factor VIII/IX Subcommittee of the International Society for Thrombosis and Hemostasis.
    Haematologica; 2000 Oct; 85(10 Suppl):40-2; discussion 42-4. PubMed ID: 11187869
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The North American Immune Tolerance Registry: contributions to the thirty-year experience with immune tolerance therapy.
    Dimichele D.
    Haemophilia; 2009 Jan; 15(1):320-8. PubMed ID: 18976249
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation.
    Hay CR, Brown S, Collins PW, Keeling DM, Liesner R.
    Br J Haematol; 2006 Jun; 133(6):591-605. PubMed ID: 16704433
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. New protocol for immune tolerance induction in acquired hemophilia.
    Nemes L, Pitlik E.
    Haematologica; 2000 Oct; 85(10 Suppl):64-8. PubMed ID: 11187874
    [Abstract] [Full Text] [Related]

  • 12. Analysis of the North American Immune Tolerance Registry (NAITR) 1993-1997: current practice implications. ISTH Factor VIII/IX Subcommittee Members.
    DiMichele DM, Kroner BL.
    Vox Sang; 1999 Oct; 77 Suppl 1():31-2. PubMed ID: 10529684
    [No Abstract] [Full Text] [Related]

  • 13. Successful immune tolerance induction with high-dose coagulation factor VIII and intravenous immunoglobulins in a patient with congenital hemophilia and high-titer inhibitor of coagulation factor VIII despite unfavorable prognosis for the therapy.
    Kubisz P, Plamenová I, Hollý P, Stasko J.
    Med Sci Monit; 2009 Jun; 15(6):CS105-11. PubMed ID: 19488019
    [Abstract] [Full Text] [Related]

  • 14. Hemophilia factor VIII therapy. Immunological tolerance. A clinical perspective.
    White GC, Greenwood R, Escobar M, Frelinger JA.
    Haematologica; 2000 Oct; 85(10 Suppl):113-6. PubMed ID: 11187862
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Characterization of antibodies to factor VIII in hemophilia A patients treated by immune tolerance therapy.
    Scandella D, Reyes H, Felch M, Sakurai Y.
    Haematologica; 2000 Oct; 85(10 Suppl):86-8. PubMed ID: 11187882
    [Abstract] [Full Text] [Related]

  • 18. Immune tolerance by intermittent factor VIII boluses in two high responder hemophilia A patients.
    Landolfi R, de Cristofaro R, Lazzareschi I, Riccardi R, Mariani G.
    Haematologica; 2000 Oct; 85(10 Suppl):73-4. PubMed ID: 11187877
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.